PTC Therapeutics Approvals and Achievements
PTC Therapeutics (PTCT) has achieved a lot recently. The latest is the August approval from the U.S. FDA of its product Evrysdi (risdiplam), the first orally administered at-home treatment for spinal muscular atrophy (SMA) in adults and children 2 months and older.
Evrysdi has been granted approvals in Brazil, Chile and Ukraine as . . .